Refine by
Biopharmaceutical Product Articles & Analysis
28 news found
Following regulatory approval, Advanced Instruments, a wholly-owned subsidiary within Patricia Industries, has now completed its acquisition of Nova Biomedical, a global provider of analytical instruments and consumables for the biopharmaceutical and clinical markets. The enterprise value amounts to USD 2.2bn. Patricia Industries has contributed USD 1.6bn in financing. The remainder of the ...
Patricia Industries’ subsidiary Advanced Instruments, a manufacturer of analytical instruments for the biopharmaceutical and clinical markets, today announced the execution of a definitive agreement to acquire Nova Biomedical, a manufacturer of innovative analytical instruments and consumables that are vital in guiding the treatment of patients and the development of ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced it has successfully achieved ISO/IEC 27017:2015 and ISO/IEC 27018:2019 certifications for information security and privacy protection in its cloud services from BSI, the business improvement and standards company. It has also achieved recertification to ISO/IEC ...
By facilitating the development of cutting-edge therapies, our products support advancements in various medical fields, including gene therapy, vaccine creation, and oncology treatments. “At Biopharma PEG, we are dedicated to providing innovative, high-performance PEG products tailored for the pharmaceutical and biotech sectors,” stated Brenda, ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from ...
Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields. These advanced PEG linkers are available in various functional groups and molecular weights ranging from 1k to 40k, offering unmatched versatility and performance for research and development in ...
ExcellGene, a renowned Swiss biologics CDMO specializing in complex protein manufacturing services, using standard CHO and HEK293 expression systems and Capricorn Scientific, a leading German manufacturer of high-quality cell culture products, have joined forces in a strategic partnership to elevate the field of biopharmaceutical ...
Dyadic is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health. bYoRNA is a French biotechnology company focused on producing ...
In this role, you will lead the planning, execution and documentation of clinical studies for our late clinical phase vaccine products. Join us in our work to give people worldwide a longer and better life. We are an entrepreneurial company and experts in global vaccine development, manufacturing, registration and commercialisation of biopharmaceutical ...
It will also allow Aktiv to communicate with the FDA to create alignment on regulatory, technical, and scientific matters associated with gaining regulatory approvals for Aktiv’s products. “We are excited to participate in this important program and delighted that our technology was recognized by the Agency for its broad potential to improve quality and safety of ...
Building on its years of experience, Creative Proteomics Pronalyse announces the launch of its metabolite identification services of biopharmaceuticals for an accurate and efficient analysis of the metabolism for your biological drugs in vivo. ...
Dusseldorf, May 16, 2022 – the German life science biotech firm, LenioBio GmbH, today announced the generation of a novel plant glycan knockout cell line that will increase the versatility and flexibility of the company’s cell-free protein synthesis (CFPS) system, ALiCE®. LenioBio’s proprietary ALiCE® platform is derived from a tobacco BY-2 plant cell lysate. ...
This agreement will bring new business to the biotech company, which is expanding its manufacturing capabilities and maintains its identity, brand, and complete team The transaction validates mAbxience differentiated core competencies in the development, manufacturing and commercialization of biopharmaceutical products With this strategic transaction the ...
The product, LMN-101, is now proceeding through Phase 2 clinical trials, and BARDA’s CARB-X program is funding development of a second-generation version of this product. ...
Milan, January 27, 2022 – InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its proprietary Saturn device in Greater China. The transaction pulled in ...
GI Innovation Co., Ltd. announced that it signed MoU for a biopharmaceutical manufacturing and development with Merck, a global science technology company. ...
Angany’s first two therapeutic products will be used in the treatment of allergy to peanuts and human allergy to cats. ...
While the accelerated development and scale-up of COVID-19 vaccines has shown what can be achieved by biopharmaceutical manufacturing, it has also highlighted the need to find ways to quickly and reliably develop and manufacture transformative drugs and therapies at scale. This project aims to address some of the manufacturing challenges faced in the pharmaceutical industry by ...
The funding comes on the heels of the recent launch of MOBILion’s first commercial High-Resolution Ion Mobility (HRIM) product, MOBIE®, which, as demonstrated in recent peer reviewed publications, addresses characterization challenges faced during biopharmaceutical drug development and quality monitoring. MOBIE® provides faster, easier and more ...
MOBILion Systems Inc. has today announced the launch of its first commercial High-Resolution Ion Mobility (HRIM) product, MOBIE, which addresses characterization challenges faced during biopharmaceutical drug development and quality monitoring. ...